ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Other Liabilities
ExpreS2ion Biotech Holding AB
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Other Liabilities
kr311k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Liabilities
kr79.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Liabilities
kr358k
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Liabilities
kr97m
|
CAGR 3-Years
29%
|
CAGR 5-Years
16%
|
CAGR 10-Years
34%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Liabilities
kr3.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Other Liabilities?
Other Liabilities
311k
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Other Liabilities amounts to 311k SEK.
What is ExpreS2ion Biotech Holding AB's Other Liabilities growth rate?
Other Liabilities CAGR 1Y
-27%
Over the last year, the Other Liabilities growth was -27%.
